STOCK TITAN
  1. Home
  2. News
  3. OLMA

Olema Pharmaceuticals, Inc. - $OLMA STOCK NEWS

Welcome to our dedicated page for Olema Pharmaceuticals news (Ticker: $OLMA), a resource for investors and traders seeking the latest updates and insights on Olema Pharmaceuticals stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Olema Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Olema Pharmaceuticals's position in the market.

News
Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Olema Pharmaceuticals, Inc. (OLMA) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.11%
Tags
conferences
-
News
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
Rhea-AI Summary
Olema Pharmaceuticals, Inc. (OLMA) announced positive interim results from a Phase 1b/2 clinical study of palazestrant (OP-1250) in combination with CDK4/6 inhibitors ribociclib and palbociclib. The company also outlined the trial design for the ongoing Phase 3 OPERA-01 monotherapy trial and announced the activation of clinical sites and initiation of patient dosing. Olema will host an investor conference call on December 6, 2023, to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.34%
Tags
clinical trial
-
News
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) granted stock options to three new employees, allowing them to purchase 57,500 shares of the Company's common stock. The options vest over four years, with an exercise price of $14.58 per share, in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.34%
Tags
none
News
Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)
Rhea-AI Summary
Olema Pharmaceuticals, Inc. (OLMA) will present new Phase 1b/2 clinical data of palazestrant (OP-1250) in combination with CDK4/6 inhibitor ribociclib and palbociclib at the San Antonio Breast Cancer Symposium on December 7, 2023. The company will also host an investor conference call on December 8, 2023, to review the data presented at the symposium and ongoing studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.73%
Tags
conferences clinical trial
-
News
Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
OLMA: Olema Pharmaceuticals Reports Strong Cash Position of $276.9M, Phase 3 Trial Progress, and Presentation at SABCS
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.13%
Tags
earnings
-
News
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Olema Pharmaceuticals, Inc. granted stock options to two new employees, allowing them to purchase a total of 85,000 shares of the company's common stock. The options vest over four years, with 25% vesting on the first anniversary and the rest vesting in 36 equal monthly installments. The options have a 10-year term and an exercise price of $14.94 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.4%
Tags
none
News
Olema Oncology to Participate in Upcoming Investor Conferences in November
Rhea-AI Summary
Olema Pharmaceuticals, a clinical-stage biopharmaceutical company, will be presenting at two investor conferences in November. The company's President and CEO, Dr. Sean P. Bohen, will participate in Fireside Chats at the Jefferies London Healthcare Conference on November 15 and the Evercore ISI HealthCONx Conference on November 29. The webcasts of the Fireside Chats will be available on Olema's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.35%
Tags
conferences
-
News
Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant
Rhea-AI Summary
Olema Pharmaceuticals announces positive results from a Phase 2 clinical study of palazestrant for the treatment of metastatic ER+/HER2- breast cancer. The study showed a median progression-free survival of 4.6 months and a clinical benefit rate of 40% across all patients. In patients with ESR1 mutations, the median progression-free survival was 5.6 months with a clinical benefit rate of 52%. Olema plans to initiate a Phase 3 clinical trial for palazestrant in second- and third-line metastatic breast cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors
Rhea-AI Summary
Olema Pharmaceuticals appoints Scott Garland to its Board of Directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.13%
Tags
management
News
Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity
Rhea-AI Summary
Olema Pharmaceuticals presents preclinical data on novel compounds targeting KAT6 at cancer conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.89%
Tags
none
Stock OLMA logo
Olema Pharmaceuticals, Inc.

Nasdaq:OLMA

OLMA Rankings

#2877 Ranked by Market Cap
#22 Ranked by Stock Gains
N/A Ranked by Dividends

OLMA Stock Data

563.25M
28.47M
3.94%
96.27%
14.49%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SAN FRANCISCO

About OLMA

olema oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. our lead program, op-1250, a potential best-in-class complete estrogen receptor antagonist (ceran), is in development to treat estrogen receptor-positive (er+), human epidermal growth factor receptor 2-negative (her2-) breast cancer. olema recently initiated a phase 1/2 dose-escalation and expansion clinical trial of op-1250. we are supported in our mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies. for more information about the company please visit www.olema.com.